The role of anti-inflammatory drugs in colorectal cancer

Dingzhi Wang, Raymond N. DuBois

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet, and lifestyle are key risk factors for colorectal cancer (CRC). Prevention of CRC has long been considered a plausible approach for the population and individuals at high risk for developing this disease. A significant effort has been made in the development of novel drugs for both prevention and treatment over the past two decades. This review highlights recent advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention and adjuvant treatment. Moreover, we focus on the molecular mechanisms underlying the antitumor effects of these drugs in CRC. The knowledge of how anti-inflammatory agents inhibit cancer formation and progression may provide a rationale for the development of more effective chemopreventive and chemotherapeutic agents with less toxicity.

Original languageEnglish (US)
Pages (from-to)131-144
Number of pages14
JournalAnnual Review of Medicine
Volume64
DOIs
StatePublished - Jan 14 2013
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Anti-Inflammatory Agents
Pharmaceutical Preparations
Nutrition
Toxicity
Epigenomics
Antineoplastic Agents
Life Style
Diet
Inflammation
Mutation
Population
Neoplasms

Keywords

  • chemoprevention
  • cyclooxygenase
  • nonsteroidal anti-inflammatory drugs (NSAIDs)
  • prostaglandins

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The role of anti-inflammatory drugs in colorectal cancer. / Wang, Dingzhi; DuBois, Raymond N.

In: Annual Review of Medicine, Vol. 64, 14.01.2013, p. 131-144.

Research output: Contribution to journalArticle

Wang, Dingzhi ; DuBois, Raymond N. / The role of anti-inflammatory drugs in colorectal cancer. In: Annual Review of Medicine. 2013 ; Vol. 64. pp. 131-144.
@article{885bfadcafc940f997477f2a18a384fb,
title = "The role of anti-inflammatory drugs in colorectal cancer",
abstract = "A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet, and lifestyle are key risk factors for colorectal cancer (CRC). Prevention of CRC has long been considered a plausible approach for the population and individuals at high risk for developing this disease. A significant effort has been made in the development of novel drugs for both prevention and treatment over the past two decades. This review highlights recent advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention and adjuvant treatment. Moreover, we focus on the molecular mechanisms underlying the antitumor effects of these drugs in CRC. The knowledge of how anti-inflammatory agents inhibit cancer formation and progression may provide a rationale for the development of more effective chemopreventive and chemotherapeutic agents with less toxicity.",
keywords = "chemoprevention, cyclooxygenase, nonsteroidal anti-inflammatory drugs (NSAIDs), prostaglandins",
author = "Dingzhi Wang and DuBois, {Raymond N.}",
year = "2013",
month = "1",
day = "14",
doi = "10.1146/annurev-med-112211-154330",
language = "English (US)",
volume = "64",
pages = "131--144",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The role of anti-inflammatory drugs in colorectal cancer

AU - Wang, Dingzhi

AU - DuBois, Raymond N.

PY - 2013/1/14

Y1 - 2013/1/14

N2 - A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet, and lifestyle are key risk factors for colorectal cancer (CRC). Prevention of CRC has long been considered a plausible approach for the population and individuals at high risk for developing this disease. A significant effort has been made in the development of novel drugs for both prevention and treatment over the past two decades. This review highlights recent advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention and adjuvant treatment. Moreover, we focus on the molecular mechanisms underlying the antitumor effects of these drugs in CRC. The knowledge of how anti-inflammatory agents inhibit cancer formation and progression may provide a rationale for the development of more effective chemopreventive and chemotherapeutic agents with less toxicity.

AB - A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet, and lifestyle are key risk factors for colorectal cancer (CRC). Prevention of CRC has long been considered a plausible approach for the population and individuals at high risk for developing this disease. A significant effort has been made in the development of novel drugs for both prevention and treatment over the past two decades. This review highlights recent advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention and adjuvant treatment. Moreover, we focus on the molecular mechanisms underlying the antitumor effects of these drugs in CRC. The knowledge of how anti-inflammatory agents inhibit cancer formation and progression may provide a rationale for the development of more effective chemopreventive and chemotherapeutic agents with less toxicity.

KW - chemoprevention

KW - cyclooxygenase

KW - nonsteroidal anti-inflammatory drugs (NSAIDs)

KW - prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=84873026456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873026456&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-112211-154330

DO - 10.1146/annurev-med-112211-154330

M3 - Article

C2 - 23020877

AN - SCOPUS:84873026456

VL - 64

SP - 131

EP - 144

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -